Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

CytRx's Tamibarotene Receives Positive Opinion From The Committee For Orphan Medicinal Products In The European Union For Treatment Of APL
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that its lead drug candidate tamibarotene has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of acute promyelocytic leukemia (APL). The positive opinion of the COMP has now been forwarded to the EU commission for final approval and publication in the community register. This favorable opinion for tamibarotene in the European Union (EU) is in addition to the Orphan Drug Designation for APL and Fast Track Designation for the treatment of adult patients with relapsed or refractory APL following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide granted by the U.S. Food and Drug Administration (FDA) in October 2007.
generic viagra online
Nurses To Stage Massive Protest At County Vote To Save San Leandro Hospital - Tuesday
Registered nurses, healthcare workers and community leaders will hold a major protest rally Tuesday at noon, outside of the Alameda County Administration building. The action, one of many occurring over the last two months, is being held on the day that the board is scheduled to vote on Sutter Health"s plan to rebuild Eden Medical Center in Castro Valley as a luxury hospital with all private rooms and 48 fewer beds. It is likely that approval will result in closure of the 122-bed San Leandro Hospital, also owned and operated by Sutter.
News of the day
World's First Cardiac Adult Stem Cell Patient Receives Infusion
Michael (Mike) Jones has become the world"s first recipient of adult cardiac stem cells to treat congestive heart failure. Jones" infusion on July 17 marks the world"s first phase-one FDA-approved clinical trial using adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of Louisville physicians at Jewish Hospital.
Nutrition

Yissum Signs A Collaboration Agreement With Aurum Ventures MKI For The Development Of Breakthrough Liver-Bypassing Oral Drug Delivery Nanotechnology

Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today at the ILSI-Biomed Israel 2009 conference, it has signed an agreement with Aurum, Ventures MKI, the technology investment arm of Mr. Morris Kahn, for the development of a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administered lipophilic drugs. The technology was developed by Prof. Simon Benita at the Hebrew University"s School of Pharmacy. Initially, Aurum will sponsor a pre-clinical feasibility study that will assess the safety and efficacy of the proprietary oral delivery of an existing drug for the treatment of solid tumors that is currently delivered intravenously. Previous pre-clinical experiments on Tacrolimus, an effective drug which prevents the rejection of transplanted organs but is poorly and variably absorbed with marked intestine and liver metabolism, resulted in 2.4 times higher bioavailability. "We are pleased to partner with Aurum on this exciting technology," said Yehuda Yarmut, Deputy CEO of Yissum. "The ability to deliver lipophilic drugs orally while bypassing specific potent barriers in the intestine and the liver carries tremendous potential. Prof. Benita, a seasoned inventor and entrepreneur and co-founder of Novagali SA, one of Yissum"s most promising spin-offs, has once again demonstrated his ingenuity in developing a novel mechanism addressing many unmet medical needs." Lipophilic drugs are poorly soluble in water, seriously limiting their bioavailability and clinical efficacy. In addition, when administrated orally 25% of these sensitive drugs cannot be absorbed because they activate an intestinal pump barrier and are metabolized in the intestines and liver. Therefore, currently many drugs present limited oral bioavailability or else are injected. Prof. Benita developed a breakthrough controlled release drug delivery system that is able to bypass intestinal and liver metabolic filters, resulting in increased bioavailability following oral administration, without any alteration of the drug molecules. This unique system allows changing the route of administration of highly lipophilic drugs from injectable to oral with potentially high bioavailability and lower side effects without affecting the normal physiological activity of the metabolic filters. Dr. Dan J. Gelvan, Managing Director for Life Sciences of Aurum Ventures MKI added, "We are very excited with the potential of the technology to offer a significant breakthrough in the oral administration of many drugs and encouraged by the pre-clinical results. We are looking forward to the results of the initial part of our collaboration which we believe will provide a novel more convenient and safer therapeutic approach compared to intravenous injections." Yissum Research Development Company Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009